Nalu Medical, Inc. — Cyborg Score 8/10

Strong
Neurostimulation Devices

Strategic Profile

Boston Scientific entered into a definitive agreement to acquire Nalu Medical in October 2025 for approximately $533 million upfront for remaining equity not owned by Boston Scientific, which has been a strategic investor since 2017. The company addresses a significant unmet need in chronic neuropathic pain management with a miniaturized, wirelessly-powered implant that differentiates it from larger legacy neurostimulation devices.

Cyborg Score Rationale

Nalu demonstrates strong commercial momentum with FDA clearance for dual indications (SCS/PNS), strategic backing from Boston Scientific since 2017, and a pending acquisition at substantial valuation. The company has commercialized technology and is scaling field operations, though as a pre-acquisition entity its long-term independence is limited.

Top Insights

  • Proprietary battery-free wireless charging architecture powered by an external wearable Therapy Disc enables a micro-implant with capabilities matching larger legacy systems.
  • In Series E funding, the company attracted new investor B Capital, demonstrating continued investor confidence in chronic pain neuromodulation market.
  • Nalu has been named one of the top 100 new products by R&D Magazine and won Gold Winner of the 2021 Medical Design Excellence Award and MedTech Visionaries Award.
  • Healthcare economics analysis shows approximately $17,903 per patient annual cost savings following spinal cord/peripheral nerve stimulation implantation through reduced healthcare utilization.

Named Competitors

  • Abbott Neuromodulation — Leading spinal cord and peripheral nerve stimulation systems
  • Medtronic Neurostimulation — Largest neurostimulation provider with comprehensive SCS/PNS portfolio
  • Stimwave Technologies — Minimally invasive peripheral nerve stimulation systems

Recent Developments

  • (October 2025) Boston Scientific announced definitive agreement to acquire Nalu Medical for ~$533M
  • (September 2025) Closed incremental Series E funding round of $50M from B Capital
  • (April 2026) Nalu Medical had approximately 252 employees across 3 continents

Open the full interactive Nalu Medical, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →